Boston Scientific (BSX) Depreciation & Amortization (CF) (2020 - 2026)

Boston Scientific (BSX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $351.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 8.0% year-over-year to $351.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 8.06% YoY), and the FY2025 full-year result was $1.4 billion, up 7.8% from the prior year.
• Depreciation & Amortization (CF) eased to $351.0 million in Q1 2026, from $365.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $365.0 million in Q4 2025 to a low of $274.0 million in Q1 2022.
• A 5-year average of $312.9 million and a median of $306.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) increased 1.38% in 2022 and climbed 11.76% in 2025, its largest moves.
• Tracing BSX's Depreciation & Amortization (CF) over 5 years: stood at $294.0 million in 2022, then gained by 6.46% to $313.0 million in 2023, then grew by 11.18% to $348.0 million in 2024, then climbed by 4.89% to $365.0 million in 2025, then decreased by 3.84% to $351.0 million in 2026.
• Business Quant data shows BSX's Depreciation & Amortization (CF) at $351.0 million in Q1 2026, $365.0 million in Q4 2025, and $342.0 million in Q3 2025.